Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · UroGen Pharma Ltd. (URGN)

UroGen revenue rises to $72.5 million; net loss narrows to $14.4 million

Positive Impact 4 of 5 guidance Written later

UroGen reported second quarter 2026 total revenue of $72.5 million, up from $24.2 million a year earlier, driven by the launch of ZUSDURI, and a net loss of $14.4 million, or $0.28 per share, compared with $49.9 million, or $1.05 per share, in the prior-year quarter. The company raised its full-year 2026 operating expense guidance to $260 million to $270 million to accelerate investment in the ZUSDURI launch and pipeline, while keeping its JELMYTO revenue guidance of $97 million to $101 million.

Key points

  • Total revenue of $72.5 million in Q2 2026 vs. $24.2 million in Q2 2025; ZUSDURI net product revenue was $50.4 million and JELMYTO was $22.0 million
  • Net loss of $14.4 million, or $0.28 per basic and diluted share, vs. $49.9 million, or $1.05 per share, a year earlier
  • Full-year 2026 operating expense guidance raised to $260 million to $270 million, including $20 million to $24 million of non-cash share-based compensation
  • Cash, cash equivalents and marketable securities totaled $108.0 million as of June 30, 2026

The filing

CompanyUroGen Pharma Ltd. (URGN)
Form8-K, current report
Filed with the SECAug 5, 2026, 8:02 AM ET
Accession number0001437749-26-025793

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.